Table 5.
Key Clinical Trials and Case Series Evaluating Number of Sentinel Lymph Nodes Removed
| Institution | Total Patients | SLN Positive Patients (%) | Mean # SLN Removed | More than 3 SLN removed (%) | Number SLN Required to Identify 1st Positive SLN (%) |
|---|---|---|---|---|---|
| University of Louisville (10 | 3882 | 1358 (35.0%) | Median 2 | 300 (22.1%)* | 1- 1011 (74.4%) |
| 2- 151 (11.1%) | |||||
| 3- 56 (4.1%) | |||||
| >3- 35 (2.6%) | |||||
| Memorial Sloan Kettering (11 | 1561 | 449 (28.8%) | 2.3 | 241 (15.4%) | 1- 338 (75.3%) |
| 2- 79 (17.6%) | |||||
| 3- 23 (5.1%) | |||||
| >3- 8 (1.8%) | |||||
| William Beaumont (12) | 720 | 167 (23.2%) | 4.4 | 77 (46.1%)* | 1- 128 (76.6%) |
| 2- 24 (14.4%) | |||||
| 3- 10 (6.0%) | |||||
| >3- 5 (3.0%) | |||||
| University of Michigan (13 | 725 | 132 (18.0%) | 2.5 | 133 (18.3%) | 1- 87 (65.9%) |
| 2- 27 (20.5%) | |||||
| 3- 16 (12.1%) | |||||
| >3- 2 (1.5%) | |||||
| Virginia Mason (14 | 541 | 129 (23.8%) | 1.95 | 57 (10.5%) | 1- 127 (98.4%) |
| 2- NR | |||||
| 3- 2 (1.6%) | |||||
| >3- NR | |||||
| University of South Florida (15) | 465 | 128 (27.5%) | Median 2 | 56 (11.0%) | 1- 114 (89.1%) |
| 2- 12 (9.4%) | |||||
| 3- 2 (1.6%) | |||||
| >3- 0 (0%) | |||||
| Ludwig Boltzman (16) | 263 | 105 (39.9%) | 1.8 | 19 (7.2%) | 1- 96 (91.4%) |
| 2- 8 (7.6%) | |||||
| 3- 1 (1.0%) | |||||
| >3- 0 (0%) | |||||
| Ohio State University (17 | 353 | 104 (29.5%) | 2.5 | 66 (18.7%) | 1- 86 (82.7%) |
| 2- 15 (14.4%) | |||||
| 3- 1 (1.0%) | |||||
| >3- 1 (1.0%) | |||||
| Mayo Clinic (18 | 472 | 103 (22%) | 2.5 | 85 (18.0%) | 1- 90 (87.4%) |
| 2- 8 (7.8%) | |||||
| 3- 3 (2.9%) | |||||
| >3- 2 (1.9%) | |||||
| Wagga Wagga (19 | 113 | 33 (29.2%) | 1.9 | NR | 1- 29 (87.9%) |
| 2- 3 (9.1%) | |||||
| 3- 1 (3.0%) | |||||
| >3- 1 (3.0%) | |||||
| Case Western Reserve | 126 | 38 (30.2%) | 2.8 | 33 (26.2%) | 1- 31 (81.6%) |
| 2- 6 (15.8%) | |||||
| 3- 1 (2.6%) | |||||
| >3- 0 (0%) | |||||
*
Represents only sentinel lymph node positive patients